---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-048960"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2021-09-27T23:59:59+00:00"
generated_at: "2026-06-29T01:14:04.004945+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences appoints Michael Amoroso as President and CEO, effective Oct 15, 2021

## Summary
- Amoroso succeeds co-founder Matt Kane, who transitions to advisor through Oct 2022.
- Annual base salary $600k; target bonus 60% of base plus $200k one-time payment in 2021.
- Inducement grants: option to buy 850k shares (4-yr vest, 25% year 1) and RSUs with $237k grant-date fair value (1-yr cliff).
- Additional option for 250k shares to be granted on first anniversary of effective date, vests over 4 years.
- Relocation assistance up to $50k (grossed up) and attorney fees up to $10k.

## SEC filing metadata
- accession: 0001564590-21-048960
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2021-09-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000156459021048960/0001564590-21-048960-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000156459021048960/dtil-8k_20210927.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-048960
- JSON: https://secwatch.observer/filing/0001564590-21-048960.json
- Plain text: https://secwatch.observer/filing/0001564590-21-048960.txt

## Key facts
- Executive change
  Mathew Kane departed as President and Chief Executive Officer at PRECISION BIOSCIENCES INC.
  - Action: agreed to cease serving
  - Role: President and Chief Executive Officer
  source text: Mr. Amoroso succeeds Mathew Kane who, as previously reported, agreed to cease serving in both capacities effective with his successor’s commencement of service with the Company and to serve as a non-employee advisor to the Company through October 1, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1357874/000156459021048960/0001564590-21-048960-index.htm
- Executive change
  Michael Amoroso was appointed as Director at PRECISION BIOSCIENCES INC.
  - Action: appointed
  - Role: Director
  source text: appointed Michael Amoroso to serve as President and Chief Executive Officer of the Company, as well as a member of the Board, in each case effective October 15, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1357874/000156459021048960/0001564590-21-048960-index.htm
- Executive change
  Michael Amoroso was appointed as President and Chief Executive Officer at PRECISION BIOSCIENCES INC.
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: appointed Michael Amoroso to serve as President and Chief Executive Officer of the Company, as well as a member of the Board, in each case effective October 15, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1357874/000156459021048960/0001564590-21-048960-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.